Skip to main content

Table 1 MDSCs in lymphoma

From: Myeloid-derived suppressor cells in hematological malignancies: friends or foes

Disease cases (n) MDSC subgroups/phenotype definition Clinical finding Mechanism/intervention Year/reference
NHL, n = 40 M-MDSCs
CD14+HLA-DRlow/−CD120blow
Increased M-MDSCs correlated with aggressive disease and suppressed immune functions Restore T cell proliferation by removing NHL M-MDSC; arginase I↑ 2011 [26]
B-NHL, n = 42 M-MDSCs
CD14+ HLA-DRlow/−
Higher MDSCs vs. healthy donor
Higher MDSCs in stage III and IV vs. stage II
Higher MDSCs in relapsed/refractory patients
Arginase I↑ 2014 [27]
B-NHL, n = 22 M-MDSCs
CD14+ HLA-DRlow/−
Higher MDSCs with a higher IPI score IL-10 induced M-MDSCs 2015 [28]
DLBCL, n = 66 M-MDSC (CD14 + HLA-DRLow)
G-MDSC
(CD33 + CD11b + Lin-HLA-DR-)
Higher M/G-MDSCs vs. healthy donor
M-MDSC number was correlated with the IPI, EFS, and number of circulating Tregs
Upregulated expression of IL-10, S100A12, and PD-L1 attributed to M-MDSC-dependent T cell suppression. T cell proliferation was restored after CD14+ depletion in DLBCL patients. 2016 [29]
T-NHL, n = 14 M-MDSCs
CD14+HLA-DRlow/−
Higher MDSCs vs. healthy donor M-MDSCs with PD-L1 expression inhibit T cell proliferation and promote the induction of FoxP3 + Treg 2009 [32]
B cell (HL + NHL), n = 124 G/PMN-MDSCs
(CD66b+CD33dimHLADR CD11b + CD16+)
Higher MDSCs vs. healthy donor Restore autologous T proliferation by depletion of CD66b + cells 2016 [33]
Extranodal NK/T cell lymphoma (ENKL), n = 32 Total MDSCs
HLA-DRCD33+CD11b+
M (CD14+), G (CD15+)
Higher MDSCs vs. healthy donor
Total MDSCs and M-MDSCs were independent predictors for DFS and OS
Higher levels of Arg-1, iNOS, and IL-17; moderate levels of TGFβ and IL-10; but lower levels of CD66b vs. healthy donors, suppressed CD4 but not CD8 activity, inhibited IFNγ but promoted IL-10, IL-17, and TGFβ. Inhibitors of iNOS, Arg-1, and ROS restore T cell proliferation 2015 [36]